помогите, пожалуйста, раздобыть статьи:
1. Hong S.-D. et al.
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
Annals of Oncology Volume 37, Issue 6, June 2026, Pages 813-824
- DOI:
http://dx.doi.org/10.1016/j.annonc.2026.01.009
HER2 biparatopic antibody-drug conjugates: is payload optimisation the next frontier?
Annals of Oncology Volume 37, Issue 9, September 2026, Pages 1196-1197
- DOI:
http://dx.doi.org/10.1016/j.annonc.2026.05.705
TROP2-directed antibody-drug conjugates: new first-line treatment for all patients with advanced triple-negative breast cancer?
Annals of Oncology Volume 37, Issue 8, August 2026, Pages 1015-1020
- DOI:
http://dx.doi.org/10.1016/j.annonc.2026.06.015
Antibody-drug conjugates and the need for third-modality regulatory science
Med 2026 Volume 7, Issue 7, 101184
- DOI:
http://dx.doi.org/10.1016/j.medj.2026.101184
Antibody-drug conjugates-opoly in ovarian cancer: a new therapeutic board game
International Journal of Gynecological Cancer, 2026, Volume 36, Issue 6, 104701
- DOI:
http://dx.doi.org/10.1016/j.ijgc.2026.104701
Antibody–drug conjugates in platinum-sensitive ovarian cancer: beyond interval-based treatment selection?
International Journal of Gynecological Cancer, Volume 36, Issue 7, July 2026, 104732
- DOI:
http://dx.doi.org/10.1016/j.ijgc.2026.104732
Promotion of tumor cell senescence by the antibody–drug conjugate, sacituzumab govitecan
Molecular Pharmacology, September 2026, Volume 108, Issue 9, Article: 100142
- DOI:
http://dx.doi.org/10.1016/j.molpha.2026.100142
Potential role of antibody–drug conjugates in gynecologic cancer patients with brain metastases
Gynecologic Oncology Reports, Available online 26 July 2026, Article: 102176
- DOI:
http://dx.doi.org/10.1016/j.gore.2026.102176
